Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.08 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)2.55M
Market Cap
$954.91M
Enterprise Value$2.30B
Total Cash (Recent Filing)$358.08M
Total Debt (Recent Filing)$604.78M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Jul 30, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding128,694,500
10 Day Avg. Volume1,586,054
30 Day Avg. Volume2,547,507
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-13.23
Enterprise Value/Market Cap2.41
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit7.81
Enterprise Value/Ebitda-303.49
Forecast
1Y Price Target
$13.19Price Target Upside68.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
NeoGenomics News
PremiumCompany Announcements
NeoGenomics Approves Key Proposals at Annual Meeting
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactThe Pathline acquisition should improve turnaround times in the Northeast, enabling NEO to win new market share.
Management StrategyThe business is executing as expected, and management believes they can return to beating estimates within a couple of quarters.
Revenue GuidanceNEO raised the FY25 guidance for revenues to reflect the inclusion of additional revenue related to the acquisition of Pathline, LLC.
Bears Say
Management ChangesThe recent management changes, including the departure of the former CEO and appointment of a new CEO, raise the risk of further senior management turnover.
Market CompetitionThe NGS solid tumor CGP market is becoming more competitive, making a 25% growth expectation for 2025-26 unlikely to materialize.
Revenue OutlookThe growth outlook for NeoGenomics Inc. appears challenging with an overly aggressive guidance for 2025.
Ownership Overview
1.12% Insiders
38.04% Mutual Funds
23.24% Other Institutional Investors
12.56% Public Companies and Individual Investors
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $6.08 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $954.91M.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Jul 30, 2025 which is in 49 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 29, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.013.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,694,500 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -34.002%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.19 (68.24% Upside)
$13.19 (68.24% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 131.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $434.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.89%
12-Months-Change
Fundamentals
Return on Equity
-8.57%
Trailing 12-Months
Asset Growth
-2.37%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Company Deck
NEO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant growth in revenue and EBITDA, expansion through acquisitions, and strong performance in clinical testing volumes and NGS revenue. However, there were challenges in the non-clinical sector, particularly in pharma and biotech spending. Despite these challenges, the company's strategic initiatives and market positioning in oncology provide a robust outlook.Read More>NEO Stock 12 Month Forecast
Average Price Target
$13.19
▲(68.24%Upside)